1.09
-0.1(-8.40%)
Currency In USD
| Previous Close | 1.19 |
| Open | 1.19 |
| Day High | 1.2 |
| Day Low | 1.08 |
| 52-Week High | 3.5 |
| 52-Week Low | 0.66 |
| Volume | 3.02M |
| Average Volume | 2.14M |
| Market Cap | 125.71M |
| PE | -0.75 |
| EPS | -1.46 |
| Moving Average 50 Days | 1.22 |
| Moving Average 200 Days | 1.17 |
| Change | -0.1 |
If you invested $1000 in Fate Therapeutics, Inc. (FATE) 10 years ago, it would be worth $236.79 as of November 05, 2025 at a share price of $1.165. Whereas If you bought $1000 worth of Fate Therapeutics, Inc. (FATE) shares 5 years ago, it would be worth $23.34 as of November 05, 2025 at a share price of $1.165.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy
GlobeNewswire Inc.
Oct 26, 2025 3:30 PM GMT
As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus Erythematosus (SLE) were treated with a single dose of FT819 with less-intensive or no conditioning chemotherapy Favorable safety p
Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer
GlobeNewswire Inc.
Oct 14, 2025 12:00 PM GMT
SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE) (the Company), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular im
Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress
GlobeNewswire Inc.
Jun 11, 2025 1:00 PM GMT
All three patients treated with FT819 following fludarabine-free conditioning regimen for severe lupus nephritis achieve Primary Efficacy Renal Response (PERR); first patient to reach 1-year follow-up continues in drug-free Definition of Remission in